Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03058705 · ClinicalTrials.gov registry record · NA
Near Infrared Fluorescence Imaging for Bladder Cancer Detection
A NA study of Bladder Cancer, sponsored by Edward Messing.
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT03058705: Completed NA study of Bladder Cancer, sponsored by Edward Messing.
NCT03058705 is a NA study of Bladder Cancer that has completed, run by Edward Messing. The registered enrollment target is 10 participants, below the 12,754-participant average among 175 other Bladder Cancer trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03058705, a NA study of Bladder Cancer, has completed, sponsored by Edward Messing.
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary outcome of this study is to determine the minimal dwell time needed for adequate detection of hexaminolevinulate HCL avid tumors using protoporphyrin IX (PpIX) near infrared fluorescence (NIRF).
Primary Outcome
The minimum time needed to observe the tumors during transurethral resection of bladder tumor (TURBT).
Conditions Studied
Interventions
- DRUG Hexaminolevulinate HCL
- DEVICE Near Infrared Fluorescence (NIRF)
Study Locations (1)
New York
- University of Rochester Medical Center - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2017-11-28 |
| Est. Completion | 2018-07-25 |
| Phase | NA |
What the finished NCT03058705 record still lists
NCT03058705 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 12,754-participant average among 175 other Bladder Cancer trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Bladder Cancer appearing as the primary indexed condition, and to 2 interventions - of which Hexaminolevulinate HCL is the first listed.
NCT03058705 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03058705 about?
NCT03058705 is a clinical study titled "Near Infrared Fluorescence Imaging for Bladder Cancer Detection". The primary outcome of this study is to determine the minimal dwell time needed for adequate detection of hexaminolevinulate HCL avid tumors using protoporphyrin IX (PpIX) near infrared fluorescence (NIRF).
What is the current status of trial NCT03058705?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2017-11-28. Estimated completion is 2018-07-25.
What conditions does trial NCT03058705 study?
This clinical trial studies the following conditions: Bladder Cancer.
What interventions are being tested in trial NCT03058705?
The interventions under investigation include: Hexaminolevulinate HCL (DRUG), Near Infrared Fluorescence (NIRF) (DEVICE).
Who is sponsoring clinical trial NCT03058705?
This trial is sponsored by Edward Messing, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03058705 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03058705's enrollment target sits among peer trials
10 167th of 175 higher than 6 of 175 other Bladder Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bladder Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy
RECRUITING · NA
-
CONFIRM: Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
-
Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support
RECRUITING · NA
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
RECRUITING · NA
-
Comprehensive Geriatric Assessment (Tests) for Bladder Cancer Participants Undergoing Radical Cystectomy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI